Linkster Therapeutics (Switzerland)

Linkster Therapeutics (Switzerland) is a Zurich-based biotechnology company focused on translational antibody engineering and the development of targeted therapeutics. According to its official website, the company "raises the bar on in vivo antibody development to create precision medicines for the right target, the right tissue & the right patient." Its work centers on overcoming a persistent bottleneck in antibody drug discovery: candidate molecules are typically engineered in vitro and only later tested in vivo, which often leads to poor accumulation in target organs and unexpectedly high enrichment in off-target organs. The company's proprietary Flycode® platform profiles large pools of peptide-barcoded antibodies in vitro, in vivo and in silico. Linkster states that this approach enables pharmacology profiling roughly 500 times faster than conventional methods and positions it at the very start of early discovery. By combining in vivo and in-tissue engineering with advanced bioinformatics, the company aims to tailor biodistribution and pharmacokinetics, improve target-specific delivery, and reduce off-target effects. Linkster Therapeutics describes itself as passion- and purpose-driven, with a team drawn from around the globe. Its researchers are said to have a 15-year track record solving fundamental questions for membrane protein targets integral to health and disease. The company continues to grow its target biology know-how and works on smart antibody library design, in vivo 3R antibody engineering, and advanced targeting strategies that incorporate tissue specificity, multi-specificity and conditionality for micro-environments. The company is headquartered in Zurich, Switzerland, and operates in the global biotechnology and pharmaceutical research market. It positions itself as a provider of next-generation precision medicines for serious and chronic diseases where patients may currently face an absence of therapy or incomplete cure. No parent company, ownership structure, or public listing is indicated in the available evidence; it appears to operate as a private, independent biotechnology firm.

Linkster Therapeutics (Switzerland) is a biotechnology company based in Zurich, Switzerland. Public information about its founding date and founders is not available in the supplied evidence. The company has emerged around a specific technological thesis: that antibody drug discovery is held back by a translational bottleneck because candidate molecules are engineered in vitro and only later tested in vivo. According to its website, this sequence often produces a massive number of candidates that accumulate poorly in target organs and enrich unexpectedly in off-target organs. To address this, Linkster Therapeutics developed the Flycode® platform, which profiles large pools of peptide-barcoded antibodies in vitro, in vivo and in silico. The company states that this platform performs pharmacology profiling 500 times faster and at the very start of early discovery. The platform is presented as a way to innovate pharmacology profiling and accelerate the development of antibody drugs, creating what the company calls the next generation of precision medicines. The company describes its team as having a 15-year track record solving fundamental questions for membrane protein targets integral for health and disease. It continues to grow its target biology know-how and works on maturing smart antibody library design and in vivo 3R antibody engineering. Linkster also states that it is a master of advanced targeting strategies, creating precision medicines with superior tissue-specificity, multi-specificity and conditionality for micro-environments. Linkster Therapeutics positions itself in the service of science, aiming to develop targeted therapeutics for patients with illnesses that have no good treatment. Its culture is described as passion- and purpose-driven, bringing together unique skills, opinions and perspectives from around the globe. The company emphasizes collaborative curiosity, exploration, prioritization, immediate feedback and trust. It is headquartered in Zurich, Switzerland, and operates in the global biotechnology and pharmaceutical research sector. No parent company, ownership structure, or public listing is indicated in the available evidence.

Precision medicine through translational antibody engineering; in vivo, high-throughput pharmacology profiling to accelerate antibody drug development and improve target specificity.

• Flycode® platform

  Profiles large pools of peptide-barcoded antibodies in vitro, in vivo and in silico; enables pharmacology profiling 500 times faster at the start of early discovery.

• Translational antibody engineering

  In vivo and in-tissue engineering to tailor biodistribution and pharmacokinetics, improving target-specific delivery and reducing off-target effects.

• Advanced bioinformatics

  Smart processes to improve antibody design and decision-making.

1. 1Linkster Therapeutics - The future of Targeted Therapeuticslinkstertx.com
2. 2Who we are - Learn more about Linkster Therapeuticslinkstertx.com
3. 3Linkster Therapeutics (Switzerland) - Wikidatawikidata.org